It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Alzheimer’s Disease: Mystery No More Read More »
In the narrow window in which patients are aware of their disease, they have sought help in clinical trials. But enrolling enough participants to make these trials count is not easy.
Trailblazer clinical trial featured in New York Times Read More »
In patients with early Alzheimer’s disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.
Trailblazer clinical trial featured in New England Journal of Medicine Read More »
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease Read More »
Alzheimer’s disease and related dementias were associated with adverse financial events starting years prior to clinical diagnosis.
Missing bill payments could be an early sign of dementia Read More »
The Clinical Research Center staff presented their findings at the 13th Clinical Trials on Alzheimer’s Disease Conference.
ANA Presentation at CTAD 2020 Read More »
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Dr. Weisman interviewed on Senior Advocates, Who’s Who Read More »
Thanks to the latest research, we can now target specific migraine pathways.
A New Treatment for Migraine Read More »
Infusion therapy may seem modern, but its origins trace as far back as 1492.
Infusions Explained Read More »
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
Dr. Weisman interviewed in Neurology Insights Read More »
